Nasal spray for Parkinson's off episodes
Part of Brain & nervous system clinical trials.
This study tests a new nasal spray called XJN010 for people with Parkinson's who have 'off' episodes—times when their regular medication wears off and symptoms come back. The goal is to see if the spray can safely and effectively help during those periods.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 85 years old.
- You have had Parkinson's disease for at least 3 years.
- You have 'off' episodes where your regular medication wears off and symptoms return.
- You are able to take levodopa (a standard Parkinson's medication) and it helps your symptoms.
- You have not had brain surgery for Parkinson's, and you do not have severe mental health conditions (like untreated depression or schizophrenia).
- You agree not to become pregnant or donate sperm during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new medication called Lu AF28996 in Chinese patients with Parkinson's disease who experience predictable on-off episodes (times when medication works well versus poorly). The study aims to see if this drug can help reduce those difficult off periods.
This Phase 2 study tests whether adding nasal insulin and glutathione can improve Parkinson’s disease symptoms and function. You would use study medicine through the nose while keeping your other treatments mostly the same during the trial.
This early-phase trial tests how safe and potentially effective KL002 is for people with advanced Parkinson’s disease. It may help reduce Parkinson’s movement symptoms, but the main early goal is safety.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.